7 Undervalued Business Support Services Stocks for Tuesday, June 20
Discover the top 7 undervalued Business Support Services stocks for Tuesday, June 20 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn’s disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Commentary & Analysis
3 Undervalued Business Support Services Stocks for Wednesday, April 26
Discover the top 3 undervalued Business Support Services stocks for Wednesday, April 26 based on AAII’s Stock Grades.Jenna Brashear
7 Undervalued Business Support Services Stocks for Wednesday, March 01
Discover the top 7 undervalued Business Support Services stocks for Wednesday, March 01 based on AAII’s Stock Grades.Jenna Brashear
7 Undervalued Business Support Services Stocks for Wednesday, January 11
Discover the top 7 undervalued Business Support Services stocks for Wednesday, January 11 based on AAII’s Stock Grades.Jenna Brashear
Is Atento SA (ATTO) Stock a Good Investment?
Learn more about Atento SA's (ATTO) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Business Support Services stock meets your investment needs.Issac Deleon
Financial Summary
| Share Statistics | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $869.6 | $286.3 | 43% |
|
| Shares Out (Mil) | 4.2 | 54.2 | 12% |
|
| Institutional Ownership | 82.6% | 92.8% | 51% |
|
| Float (Mil) | 23.6 | 39.7 | 31% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 334 | 534 | 51% |
|
| Price Change (52-week) |
na | 58.7% | na |
|
| Growth | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($64) | ($43) | 14% |
|
| EPS (TTM) | ($15.890) | ($1.400) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($63) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $998 | $160 | 41% |
|
| Valuation | ATTO | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.77 | na |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (87.8%) | (47.3%) | 6% |
|
| ROE | 102.2% | (55.0%) | 96% |
|
| Liabilities to Assets | 9.2% | 29.6% | 5% |
|
| F-Score | 1 | 2 | na |
|
Attovia Therapeutics, Inc. did not pass any screens on 8/20/2026.
